Clinical Trials New Brain-Penetrant CDK2 Inhibitor Begins Human Trials On May 29, 2026, the first patient was dosed with AL-605, a new CDK2 inhibitor developed by Alaw Therapeutics, in a clinical trial. Here's why that's important for MEF2C... 2026-06-13
